Celcuity Inc. (CELC) Stock Analysis 2026

HealthcareBiotechnology

BriMind AI Score

Proprietary
32
Weak
Price CAGR
18.2%
1Y Return
-8.1%
Analyst Upside
+137.1%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

Key Financial Metrics

Celcuity Inc. doesn't carry a meaningful trailing P/E right now, generates $-72.0M in free cash flow, hasn't disclosed a debt/equity ratio, and converts shareholder equity into profit at a -1433.7% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Market Cap
$3.19B
P/E (Forward)
-815.63
EPS (Trailing)
$-4.31
EPS (Forward)
$-0.08
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
Return on Equity
-1433.7%
Return on Assets
-25.8%
Free Cash Flow
$-72.0M
Current Ratio
8.93
Quick Ratio
8.68
Beta
0.11
Dividend Yield
None
Payout Ratio
0.0%
Insider Ownership
10.2%
Inst. Ownership
112.7%
Short % Float
33.7%
Book Value / Share
$-0.26

Wall Street Analyst Consensus

Wall Street analysts covering Celcuity Inc. currently haven't converged on a clear consensus rating, with a mean 12-month price target of $154.69. Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

Mean Target$154.69

Technical Price Signals

CELC is currently in a mixed technical position. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

50-Day MA
$80.07
200-Day MA
$101.60

Further Reading

Research and guides that put CELC’s numbers in context — how to read the filings behind them, and the frameworks we use to score them.

FundamentalsFactor Investing Guide 2026: Value, Momentum, Quality & Low Volatility — Which Factors Work?Risk ManagementHow to Build Your First Investment Portfolio: Risk Tolerance, Asset Allocation & Your First 5 FundsFundamentalsWarren Buffett Retired 2026: Berkshire Portfolio Under Greg AbelBeginnerWhat Is an AI Stock Score? How BriMindInvest Ranks Stocks

More Healthcare Stock Analysis

In-depth reports on companies operating alongside CELC — business models, bull and bear cases, and the metrics that matter.

SRPTSarepta Therapeutics, Inc.BiotechnologyINSMInsmed IncorporatedBiotechnologyCORTCorcept Therapeutics IncorporatedBiotechnologyREGNRegeneron Pharmaceuticals, Inc.BiotechnologyINCYIncyte CorporationBiotechnologyRXRXRecursion Pharmaceuticals, Inc.BiotechnologyVRTXVertex Pharmaceuticals IncorporatedBiotechnologyBEAMBeam Therapeutics Inc.Biotechnology

Unlock the Full CELC Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
Data sources: Financial metrics and market data sourced from company SEC filings, earnings releases, and investor relations disclosures. Price data, analyst consensus targets, and fundamental financials provided by financial market data providers. ETF data sourced from official fund prospectuses and index provider publications. AI scores and price targets are proprietary estimates — see our Methodology and Disclaimer for details.
← Back to Home · Browse All Stock Analysis